An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

1,499

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

May 22, 2024

Study Completion Date

February 3, 2025

Conditions
Neoplasms by Site
Interventions
BIOLOGICAL

Relatlimab

BIOLOGICAL

Nivolumab

BIOLOGICAL

BMS-986213

Relatlimab + Nivolumab

Trial Locations (54)

1011

Local Institution - 0017, Lausanne

1090

Local Institution - 0023, Vienna

Local Institution - 0024, Vienna

2060

Local Institution - 0029, North Sydney

2100

Local Institution - 0028, Copenhagen

2730

Local Institution - 0020, Herlev

3000

Local Institution - 0033, Melbourne

4120

Local Institution - 0031, Brisbane

4215

Local Institution - 0039, Southport

6009

Local Institution - 0032, Nedlands

8091

Local Institution - 0016, Zurich

10065

Local Institution - 0005, New York

13385

Local Institution - 0038, Marseille

18103

Local Institution - 0047, Allentown

20141

Local Institution - 0014, Milan

21287

Local Institution - 0004, Baltimore

29010

Local Institution - 0046, Málaga

31008

Local Institution - 0006, Pamplona

31059

Local Institution - 0026, Toulouse

33612

Local Institution - 0058, Tampa

35128

Local Institution - 0035, Padua

44093

Local Institution - 0037, Nantes

45122

Local Institution - 0007, Essen

48201

Local Institution - 0011, Detroit

60637

Local Institution - 0003, Chicago

60714

Local Institution - 0048, Niles

63110

Local Institution - 0044, St Louis

69495

Local Institution - 0036, Pierre-Bénite

74078

Local Institution - 0040, Heilbronn

75246

Local Institution - 0057, Dallas

77030

Local Institution - 0045, Houston

80045

Local Institution - 0053, Aurora

80131

Local Institution - 0013, Napoli

94800

Local Institution - 0018, Villejuif

97080

Local Institution - 0041, Würzburg

97213

Local Institution - 0002, Portland

98109

Local Institution - 0008, Seattle

1040045

Local Institution - 0052, Chuo-ku

4118777

Local Institution - 0054, Sunto-gun

4668560

Local Institution - 0055, Nagoya

92093-0698

Local Institution - 0043, La Jolla

02215

Local Institution - 0001, Boston

55905-0001

Local Institution - 0051, Rochester

15232-1305

Local Institution - 0010, Pittsburgh

M5G 2M9

Local Institution - 0049, Toronto

G1J 1Z4

Local Institution - 0050, Québec

00290

Local Institution - 0021, Helsinki

0608543

Local Institution - 0059, Sapporo

1066 CX

Local Institution - 0025, Amsterdam

0379

Local Institution - 0019, Oslo

08035

Local Institution - 0015, Barcelona

NW1 2PG

Local Institution - 0027, London

SW3 6JJ

Local Institution - 0022, London

M20 4BX

Local Institution - 0034, Manchester

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01968109 - An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Biotech Hunter | Biotech Hunter